A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months
No
Mary Mulcahy, MD
Principal Investigator
Northwestern University
United States: Food and Drug Administration
TS-102
NCT01483027
January 2012
Name | Location |
---|---|
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
Northwestern Memorial Hospital | Chicago, Illinois 60611 |
UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California 94115 |
University of Washington | Seattle, Washington 98195 |
Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
University of Louisville | Louisville, Kentucky 40202 |
Washington University | St. Louis, Missouri 63110 |
Albany Medical Center | Albany, New York 12208 |
Karmanos Cancer Institute | Detroit, Michigan 48201 |
Indiana University School of Medicine | Indianapolis, Indiana 46204 |
Moffitt Cancer Center & Research Institute | Tampa, Florida 33612-9497 |
University of Virginia Health System | Charlottesville, Virginia 22903 |
The Johns Hopkins Hospital | Baltimore, Maryland 21205 |
Medical College of Wisconsin, Inc. | Milwaukee, Wisconsin 53226 |
Legacy Meridian Park Medical Center | Tualatin, Oregon 97062 |
Spectrum Health / Advanced Radiology Services | Grand Rapids, Michigan 49506 |
Mt Sinai Medical School, Tisch Cancer Institute | New York, New York 10029-6574 |